Time New York: Sun 30 Apr 03:06 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Actis portfolio company M diS Group announces the acquisition of Winthrop Pharma Senegal from Sanofi

Actis portfolio company M diS Group announces the acquisition of Winthrop Pharma Senegal from Sanofi

PR Newswire

LONDON, April 19, 2017 /PRNewswire/ — Actis, a leading growth markets investor, today announced that its portfolio company M diS, a major pharmaceutical company based in Tunisia, has acquired Winthrop Pharma Senegal (WPS) from Sanofi.

Actis invested in M diS at the end of August 2016 with the vision to work alongside the founder Dr Lassaad Boujbel and Management to build a leading pan- African and Middle East player. Through this acquisition, M diS aims to actively develop the business in Francophone Sub-Saharan Africa from a Senegalese base.


WPS is a significant operator in the pharmaceuticals sector in French-speaking sub-Saharan Africa (FSSA). M diS’ acquisition includes a 34,000m² manufacturing facility in the Rufisque district of Dakar, Senegal. The plant is one of the most important production platforms in Western Africa and benefits from Senegalese and various West & Central African Ministry of Health approvals, including authorisation to handle controlled substances. The plant exports a substantial part of its output.

M diS has more than 720 marketing authorizations worldwide, 480 of which are in Africa, and is constantly expanding its international presence with a subsidiary in Algeria and the creation of M diS International in the Czech Republic, making it the first Tunisian multinational in the pharmaceutical field.

This acquisition increases the number of M diS production sites, which currently include: M diS laboratories in Tunisia, NEAPOLIS PHARMA laboratories in Tunisia, Inpha-M diS laboratories in Algeria and M diS International laboratories in the Czech Republic.

M diS is currently present in 16 countries in FSSA including Senegal, Cote d’Ivoire and Cameroun. The FSSA pharmaceutical market is estimated at more US$2.5bn and forecasted to grow at close to double digit rates over the next five years, driven by emergence of a middle class, improved healthcare infrastructure, external donator support for healthcare system and rise of insurance. The region’s branded generics penetration is among the lowest in the world but is projected to grow rapidly over the same period.

Dr Lassaad Boujbel, founder of M diS, said: “When M diS first partnered with Actis last year, I was particularly pleased by how aligned they were with us in our intention to grow M diS into a leading regional platform. This is a significant strategic step towards that goal.”

Commenting on the acquisition, Hichem Omezzine, Director at Actis, said: “This acquisition is extremely exciting. Not only will M diS benefit from a world class facility with significant production capacities and space available for further expansion, but the business is also gaining an extremely strong platform from which to access the Sub-Saharan African market.”

About M diS group

During the 20 years of practice and technical expertise in the pharmaceutical industry, the M diS Group has built its position as the market leader in branded generics in its native country, Tunisia.

M diS manufactures a broad portfolio of quality, affordable medicines with strong recognition and trust among doctors and patients. Its products belong to several therapeutic areas, in particular to the chronic pathologies of various specialties such as cardiology, diabetology, neuropsychiatry, cancerology, pain, allergies, gastrology, etc. M diS also manufactures and markets a wide range of leading-edge medicines such as “biosimilar” products for the treatment of diseases such as deep vein thrombosis, pulmonary embolism, infertility and multiple sclerosis.

M diS continues developing high-quality medicines with its market-leading production systems, quality control, quality assurance and R&D capabilities.

About Actis

Actis is a leading investor in growth markets, delivering consistent competitive returns, responsibly. It has a growing portfolio of investments across Asia, Africa and Latin America and has raised over US$12 billion since inception.

The firm invests through insights gained from trusted relationships and local knowledge, deep sector expertise and an unparalleled heritage, set within a culture of active ownership.

Applying developed market disciplines to growth markets, an established team of c. 100 investment professionals in ten countries identify investment opportunities in response to two trends: rising domestic consumption and the need for sustained investment in infrastructure across private equity, energy and real estate asset classes.

Actis is a signatory to the United Nations backed Principles for Responsible Investment (UNPRI), an investor initiative developed by the UNEP FI and the UN Global Compact. Actis targets consistent superior returns across asset classes over the long-term, bringing financial and social benefits to investors, consumers and communities. It calls this the positive power of capital.

www.act.is

For more information:


John Thompson

Nabil SAADAOUI

+44 (0)20 7234 5107

CEO Les Laboratoires M diS

jthompson@act.is

n.saadaoui@medis.com.tn

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/actis-portfolio-company-medis-group-announces-the-acquisition-of-winthrop-pharma-senegal-from-sanofi-300441774.html

SOURCE Actis

<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.